Twin Focus Capital Partners, LLC Alkermes Plc. Transaction History

Twin Focus Capital Partners, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$23.37 - $28.68 $1.87 Million - $2.3 Million	80,032 New	80,032 $2.22 Million
Q4 2018 Feb 13, 2019	SELL	$27.94 - $44.61 $908,050 - $1.45 Million	-32,500 Closed	0 $0
Q2 2018 Aug 10, 2018	SELL	$40.56 - $51.36 $304,200 - $385,200	-7,500 Reduced 18.75%	32,500 $1.34 Million
Q3 2017 Nov 13, 2017	BUY	$49.16 - $54.45 $1.97 Million - $2.18 Million	40,000	40,000 $2.03 Million

361

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.84B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Twin Focus Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Twin Focus Capital Partners, LLC with notifications on news.